
NYSE:TMO
This summary was created by AI, based on 18 opinions in the last 12 months.
Thermo Fisher Scientific (TMO) has garnered a mix of appreciation and cautious observation from experts in the healthcare and life sciences sectors. Most analysts agree on its solid reputation as a 'pick and shovel' supplier within the healthcare industry, providing crucial tools for drug development and research. Although TMO faced challenges such as declining margins due to a funding crunch in biotechnology and greater market volatility stemming from geopolitical tensions, many view its extensive global footprint and robust revenue models as strengths. Analysts note the company's positive long-term prospects, bolstered by a recent turnaround in pharma and biotech spending. Despite trading around historical highs, expert consensus leans towards steady but cautious growth rather than aggressive wealth building.